MRNA ’s Next Chapter Has Nothing to Do With COVID-19 Vaccines
It’s safe to say that before the development of the Pfizer-BioNTech and Moderna COVID-19 vaccines, most people hadn’t thought about messenger RNA, or mRNA, since high school science class—if ever. The molecule plays a pivotal role in the body, carrying the recipes for making various proteins to the parts of cells that produce them. But “mRNA” wasn’t exactly a common phrase until Pfizer-BioNTech and Moderna harnessed the genetic material’s power to teach the body to make a piece of a protein found on the COVID-19 virus’ surface, thus training it to fight the real thing, were i...
Source: TIME: Science - August 2, 2021 Category: Science Authors: Jamie Ducharme Tags: Uncategorized healthscienceclimate medicine Source Type: news

Johnson & Johnson Reports Q2 2021 Results
New Brunswick, N.J. (July 21, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter. “Our second-quarter results showcase Johnson & Johnson’s diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulato...
Source: Johnson and Johnson - July 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

CRISPR Therapy Fights Rare Disease Where Protein Clogs Organs
TUESDAY, June 29, 2021 -- Early research suggests that CRISPR gene-editing technology may some day lead to dramatic relief for patients struggling with amyloidosis, a rare but serious disease that can trigger organ failure. " There are many... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 29, 2021 Category: General Medicine Source Type: news

'A new era of medicine': In a first for CRISPR, Intellia edits cells inside the body
In a first for the still-young field of CRISPR gene editing, Intellia Therapeutics (Nasdaq: NTLA) has successfully edited DNA inside the human body. The Cambridge biotech, working with Regeneron Pharmaceuticals (Nasdaq: RGEN), genetically altered liver cells in six patients with a genetic nerve disorder called transthyretin amyloidosis in a Phase 1 study. On Saturday, Intellia and Regeneron published data showing that the treatment had reduced levels of a disease-causing protein by 52% at a relatively… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 28, 2021 Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news

Alnylam Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Investigational Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 24, 2021-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - June 24, 2021 Category: Drugs & Pharmacology Source Type: news

Attralus touts amyloid imaging research at SNMMI 2021
Biopharmaceutical company Attralus is directing attention to research presente...Read more on AuntMinnie.comRelated Reading: ASNC releases directive on cardiac amyloidosis imaging JNM: Florbetaben-PET detects cardiac amyloidosis (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 15, 2021 Category: Radiology Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Updated Data Demonstrate Significant Improvement in Hematologic Complete Response with DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, N.J., May 26, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the Phase 3 ANDROMEDA study, which evaluated DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare blood cell disorder associated with the deterioration of vital organs, most notably the heart, kidneys and liver.[1] Longer-term results from a median follow-up of 20.3 months showed rates of hematologic complete response (hemCR) remained significantly higher in patients treated with DARZALEX FASPRO®...
Source: Johnson and Johnson - May 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Novel Treatment Approach in Transthyretin Amyloidosis Novel Treatment Approach in Transthyretin Amyloidosis
A potential new treatment option aimed at clearing amyloid deposits from vital organs has shown promising preliminary results in an initial clinical trial.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - April 22, 2021 Category: Intensive Care Tags: Neurology & Neurosurgery News Source Type: news

Jonathan Wall receives $1.79 million to develop new amyloidosis treatment
(University of Tennessee Health Science Center) The National Institute of Diabetes and Digestive and Kidney Diseases recently awarded Jonathan Wall, PhD, professor in the University of Tennessee Health Science Center's Graduate School of Medicine in Knoxville, a $1.79 million grant for his study titled " Developing a Theranostic Immunotherapy for Systemic Amyloidosis. " (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 16, 2021 Category: International Medicine & Public Health Source Type: news

Curcumin for amyloidosis and lipid metabolism -- a novel insight
This study demonstrates that curcumin is a PPARα/γ dual activator and may affect expression levels of proteins involved in amyloid deposition and other metabolism functions in a complex manner. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 26, 2021 Category: International Medicine & Public Health Source Type: news

Mayo Clinic Q & amp;A podcast: Symptoms for cardiac amyloidosis overlap with other conditions
Cardiac amyloidosis is irreversible thickening of the heart muscle that typically presents as a form of congestive heart failure. It is overlooked often because the symptoms can masquerade as other conditions. Unfortunately, there aren't any preventive strategies for cardiac amyloidosis, says Dr. Melissa Lyle, a Mayo Clinic cardiologist. "So the key, really, is early detection," says [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - February 19, 2021 Category: Databases & Libraries Source Type: news

Did Unrecognized Cardiac Amyloidosis Hinder Recent HFpEF Trials? Did Unrecognized Cardiac Amyloidosis Hinder Recent HFpEF Trials?
Routinely screening for cardiac amyloid and excluding those patients might increase the chances of finding efficacious treatments for heart failure with preserved ejection fraction, researchers suggest.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 5, 2021 Category: Consumer Health News Tags: Cardiology News Source Type: news

Johnson & Johnson Reports 2020 Fourth-Quarter and Full Year Results
New Brunswick, N.J. (January 26, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2020. “Our notable full year performance reflects the continued confidence from patients, physicians, customers and consumers in our life-enhancing products and medicines, particularly throughout the COVID-19 pandemic,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m incredibly proud of our Johnson & Johnson teams around the world for going above and beyond to meet stakeholder needs. These efforts, and our commitment to families around the world a...
Source: Johnson and Johnson - January 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

FDA Approves First and Only Treatment for AL Amyloidosis FDA Approves First and Only Treatment for AL Amyloidosis
Accelerated approval has been granted to daratumumab in combination with bortezomib, cyclophosphamide, and dexamethasone for treatment of newly diagnosed light chain amyloidosis.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 20, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves First and Only Treatment for AL Amyloidosis FDA Approves First and Only Treatment for AL Amyloidosis
Accelerated approval has been granted to daratumumab in combination with bortezomib, cyclophosphamide, and dexamethasone for treatment of newly diagnosed light chain amyloidosis.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 20, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
January 15, 2021 (HORSHAM, Pa.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.[1] DARZALEX FASPRO® is the first and only FDA-approved treatment for patients with this blood cell disorder that is associated with the production of an abnormal protein, which leads to th...
Source: Johnson and Johnson - January 16, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Darzalex Faspro (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
January 15, 2021 (HORSHAM, Pa.)– The Janssen Pharmaceutical Companies of Johnson& Johnson announced today the U.S. Food and Drug Administration (FDA) approval of Darzalex Faspro® (daratumumab and hyaluronidase-fihj), a subcutaneous... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 15, 2021 Category: Drugs & Pharmacology Source Type: news

Positive Phase 3 Trial in hATTR Amyloidosis With Polyneuropathy Positive Phase 3 Trial in hATTR Amyloidosis With Polyneuropathy
The RNAi therapeutic vutrisiran met its primary and secondary endpoints in the HELIOS-A phase 3 study of patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 9, 2021 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news

New treatment uncovered for AL amyloidosis to be announced at ASH Meeting
(SWOG) Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, have shown that isatuximab, a monoclonal antibody approved for the treatment of multiple myeloma, can effectively treat relapsed refractory AL amyloidosis, findings to be announced at the 2020 Annual Meeting of the American Society of Hematology (ASH), held virtually December 5-8, 2020. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 7, 2020 Category: Cancer & Oncology Source Type: news

Inotersen less costly for treatment of polyneuropathy in hereditary amyloidosis
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 1, 2020 Category: Drugs & Pharmacology Source Type: news

Utility of Biomarkers in Cardiac Amyloidosis Utility of Biomarkers in Cardiac Amyloidosis
This paper presents an overview of the utility of cardiac biomarkers in determining disease progression, response to therapies, and prognosis in patients with cardiac amyloidosis.JACC: Heart Failure (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 27, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Racial/ethnic minorities comprise small portion of patients referred with AL amyloidosis
(Boston University School of Medicine) Despite being theoretically at an increased risk for AL amyloidosis, underrepresented minorities make up only a small percentage of patients seen at specialized treatment centers for this disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 10, 2020 Category: Cancer & Oncology Source Type: news

Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio
RARITAN, N.J., November 5, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today more than 35 company-sponsored studies, including 10 oral presentations, will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually December 5-8, 2020.In multiple myeloma, highlights include Phase 1b/2 results for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel); new and updated data for the anti-CD38 monoclonal antibody DARZALEX® (daratumumab) and the subcutane...
Source: Johnson and Johnson - November 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson Reports 2020 Third-Quarter Results
New Brunswick, N.J. (October 13, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2020. “Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of the relentless passion and Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 ...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Wall awarded $385,000 grant to study amyloidosis treatment options
(University of Tennessee Health Science Center) Jonathan Wall, PhD, professor in the University of Tennessee Health Science Center's Graduate School of Medicine in Knoxville and director of the Amyloidosis and Cancer Theranostics, has been awarded a two-year grant totaling $385,000 from the National Institute on Aging, part of the National Institutes of Health to study new treatments for systemic amyloidosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 6, 2020 Category: International Medicine & Public Health Source Type: news

TTG Imaging Solutions to distribute MiE PET system
Diagnostic imaging equipment firm TTG Imaging Solutions has received exclusive...Read more on AuntMinnie.comRelated Reading: Groups ask NRC to allow virtual radiotracer training TTG Imaging acquires NIS ASNC, ASE win CMS recognition for ImageGuide Registry PET shows meditating increases blood flow in heart disease patients ASNC releases directive on cardiac amyloidosis imaging (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 28, 2020 Category: Radiology Source Type: news

Attralus Launches with $25 Million Series A Financing from venBio Partners to Transform Treatment for Patients with Systemic Amyloidosis
Leverages proprietary pan-amyloid targeting agents with potential to diagnose and reverse the underlying pathology of systemic amyloid diseases, including AL and ATTR amyloidosis SOUTH SAN FRANCISCO, Calif., Sept. 14, 2020 -- (Healthcare Sales & Marketi... Biopharmaceuticals, Venture Capital Attralus, amyloidosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 14, 2020 Category: Pharmaceuticals Source Type: news

Outcomes in Patients With Cardiac Amyloidosis and ICD Outcomes in Patients With Cardiac Amyloidosis and ICD
This study compared survival in patients with cardiac amyloidosis with and without a primary prevention implantable cardioverter-defibrillator. Did an ICD improve outcomes?Europace (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 31, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Transthyretin Cardiac Amyloidosis in Severe Aortic Stenosis Transthyretin Cardiac Amyloidosis in Severe Aortic Stenosis
A new study explores whether it is feasible to perform TAVI in patients with aortic stenosis and probable concomitant transthyretin amyloidosis.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 24, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

New York man, 52, walks again after learning back pain was a rare form of HEART DISEASE 
Rick Weber, 52, from New York, learned that the pain in his back and legs was being caused by cardiac amyloidosis, abnormal protein deposits in his heart that didn't allow blood to flow properly. (Source: the Mail online | Health)
Source: the Mail online | Health - June 21, 2020 Category: Consumer Health News Source Type: news

New Option for AL Amyloidosis: Daratumumab Added to CyBorD New Option for AL Amyloidosis: Daratumumab Added to CyBorD
The addition of daratumumab to the standard CyBorD regimen produced'substantial'increases in hematologic response rates and delayed the time to organ failure.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 18, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Subcutaneous Daratumumab Combination Resulted in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, NJ, June 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the first randomized Phase 3 study investigating subcutaneous daratumumab[i] in the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare and potentially fatal disease.[1],[2] The data demonstrated subcutaneous daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) resulted in a higher hematologic complete response rate (CR), (53 percent vs. 18 percent [P
Source: Johnson and Johnson - June 15, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

What Is the Main Cause of Amyloidosis
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 5, 2020 Category: General Medicine Source Type: news

Untangling the Physiology of Transthyretin Cardiac Amyloidosis Untangling the Physiology of Transthyretin Cardiac Amyloidosis
A new study investigates echocardiographic phenotypes of transthyretin cardiac amyloidosis, the most common etiology of restrictive cardiomyopathy, identifying parameters predictive of survival.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 11, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Unbiased proteomic approach identifies pathobiological profiles in the brains of preclinical models of repetitive mild traumatic brain injury, tauopathy, and amyloidosis - Ojo JO, Crynen G, Algamal M, Vallabhaneni P, Leary P, Mouzon B, Reed JM, Mullan M, Crawford F.
No concerted investigation has been conducted to explore overlapping and distinct pathobiological mechanisms between repetitive mild traumatic brain injury (r-mTBI) and tau/amyloid proteinopathies considering the long history of association between TBI... (Source: SafetyLit)
Source: SafetyLit - April 6, 2020 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Study of rare genetic disorder that effects the eyes
(Shinshu University) Small gauge vitrectomy for vitreous amyloidosis and subsequent management of secondary glaucoma in patients with hereditary transthyretin amyloidosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 3, 2020 Category: International Medicine & Public Health Source Type: news

Drug Trial Snapshot: ONPATTRO
ONPATTRO is a drug for the treatment of nerve damage in adult patients with hereditary transthyretin-mediated amyloidosis. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 30, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Long Delays in Amyloidosis Dx, Even With Established Cardiac Care Long Delays in Amyloidosis Dx, Even With Established Cardiac Care
The underrecognized disease is rare and diagnosis complicated by a lack of awareness and heterogeneity of symptoms at presentation.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 21, 2020 Category: Cancer & Oncology Tags: Cardiology News Source Type: news

anti-cancer drug safe and effective for treating light chain (AL) amyloidosis
(Boston University School of Medicine) There's a new treatment option available for patients with AL amyloidosis: daratumumab. Studied in a prospective clinical trial, only one of the two clinical trials of this agent in AL amyloidosis worldwide, researchers have found this anti-cancer drug to be well tolerated and effective in patients with relapsed AL amyloidosis when used with appropriate pre- and post-infusion medications. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 27, 2020 Category: International Medicine & Public Health Source Type: news

ASNC, ASE win CMS recognition for ImageGuide Registry
The American Society of Nuclear Cardiology (ASNC) and the American Society...Read more on AuntMinnie.comRelated Reading: ASNC releases directive on cardiac amyloidosis imaging Imaging groups oppose cuts in myocardial PET rates ACC, ASE release echocardiography training guidance ASNC names Beanlands as president (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 22, 2020 Category: Radiology Source Type: news

Ionis Appoints Onaiza Cadoret-Manier As Chief Corporate Development and Commercial Officer
CARLSBAD, Calif., Jan. 9, 2020 -- (Healthcare Sales & Marketing Network) -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced the appointment of Onaiza Cadoret-Manier as chief corporate development and co... Biopharmaceuticals, Neurology, Personnel Ionis Pharmaceuticals, RNA-targeted, antisense, transthyretin amyloidosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 9, 2020 Category: Pharmaceuticals Source Type: news

Treatment of Cardiac Transthyretin Amyloidosis: An Update Treatment of Cardiac Transthyretin Amyloidosis: An Update
This article presents an overview of several new pharmacological agents available to treat cardiac transthyretin amyloidosis, a rare and difficult to diagnose genetic disorder.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 1, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Subtle Cognitive Difficulties May Predict Amyloidosis
TUESDAY, Dec. 31, 2019 -- Individuals with objectively-defined subtle cognitive difficulties (Obj-SCD) have faster amyloid accumulation and faster entorhinal cortical thinning compared with cognitively normal (CN) individuals, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 31, 2019 Category: Pharmaceuticals Source Type: news

C2N Diagnostics Brings Home Positive Results for Alzheimer ’s Test
C2N Diagnostics’s detection test for Alzheimer’s disease is showing off some strong data coming out of the 12th Annual Clinical Trials in Alzheimer’s Disease conference. The St. Louis-based company said results from a study show the Aptus-Aβ test strongly predicts the presence of brain amyloidosis in a diverse population. C2N Diagnostics said its blood-based in vitro diagnostic is being developed to predict amyloid PET scan results. It combines into a ratio, the concentration of amyloid beta (Aβ) isoforms Aβ42 and Aβ40 in ...
Source: MDDI - December 10, 2019 Category: Medical Devices Authors: Omar Ford Tags: IVD Source Type: news

Medical News Today: What is amyloidosis?
Amyloidosis is a condition that causes abnormal proteins to grow on a person's organs. It can cause a variety of symptoms, depending on the organs involved. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 24, 2019 Category: Consumer Health News Tags: Endocrinology Source Type: news

Changes in the Blood Could Hold Key for Better Alzheimer ’s Detection
Researchers at the University of Turku have discovered new changes in blood samples associated with Alzheimer’s disease. A new study was conducted on disease-discordant Finnish twin pairs: one sibling suffering from Alzheimer's disease and the other being cognitively healthy. The researchers used the latest genome-wide methods to examine the twins' blood samples for any disease-related differences in epigenetic marks which are sensitive to changes in environmental factors. These differences between the siblings were discovered in multiple different genomic regions. Development of the late-onset form of Al...
Source: MDDI - October 15, 2019 Category: Medical Devices Authors: MDDI Staff Tags: R & D Source Type: news

AL Amyloidosis: Advances in Diagnostics and Treatment AL Amyloidosis: Advances in Diagnostics and Treatment
Recent advances have led to promising new diagnostic strategies and treatment options for AL amyloidosis.Nephrology Dialysis Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 2, 2019 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news

Cardiac amyloidosis — Treatment options
(Source: MayoClinic.com Full Feed)
Source: MayoClinic.com Full Feed - September 26, 2019 Category: Consumer Health News Source Type: news

Cardiac amyloidosis — What is amyloid and how does it affect the heart
(Source: MayoClinic.com Full Feed)
Source: MayoClinic.com Full Feed - September 26, 2019 Category: Consumer Health News Source Type: news